The NFκB Responsive Luciferase Reporter HeLa Stable Cell Line is a human cervical cancer-derived cell line engineered to provide a sensitive and reliable platform for monitoring NFκB signaling activity. This cell line stably expresses firefly luciferase under the control of NFκB response elements, offering a powerful tool to study NFκB pathway activation in vitro.
Luciferase expression in this cell line is directly correlated with NFκB activation, making it an ideal reporter system for quantifying pathway activity in response to a range of stimuli. Upon activation, NFκB translocates to the nucleus and binds to its response elements, inducing luciferase expression and generating a luminescent signal measurable by standard luciferase assays. This system enables precise, real-time tracking of NFκB transcriptional activity in live cells.
Key Features:

  
Sensitive, quantitative readout: Luminescence intensity reflects NFκB transcriptional activity, allowing for accurate analysis of pathway activation.
  
Responsive to diverse stimuli: Suitable for studying NFκB responses to TNFα, IL-1, oxidative stress, UV irradiation, and pathogen-associated triggers.
  
Stable integration: The luciferase reporter construct, containing four NFκB binding sites and a minimal promoter, was stably integrated alongside a hygromycin resistance gene. Clones were selected and screened for strong induction following TNFa stimulation.
  
Robust performance: Delivers high signal-to-background ratio and consistent, reproducible results across experimental replicates.

This cell line retains characteristics of its HeLa origin and is ideal for drug screening, inflammation and immune response research, and transcription factor pathway analysis. It is compatible with both manual and automated luminescence detection systems, providing flexibility for high-throughput screening and mechanistic investigations.